A recently developed SYK inhibitor, TAK-659 (61, –, 64), is in clinical trials (NCT02000934, NCT02323113, NCT02834247, and NCT02954406), and preliminary clinical data indicate that it is nontoxic and highly effective against a subset of lymphomas (63, –, 66). The gene discussed is SYK; the disease is lymphoma.